Premium
Zenith Capital Corporation (EM) (ZHCLF)
USOTC
Hot Features
Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
Zenith Capital Corp., a biotechnology investment company, engages in the development of bromodomain inhibitors for the treatment of cancer and other disorders with unmet medical needs. The company’s lead compound ZEN-3694, which is in Phase 2 clinical trial for the treatment of metastatic castration... Zenith Capital Corp., a biotechnology investment company, engages in the development of bromodomain inhibitors for the treatment of cancer and other disorders with unmet medical needs. The company’s lead compound ZEN-3694, which is in Phase 2 clinical trial for the treatment of metastatic castration resistant prostate cancer in collaboration with Astellas and Newsoara, as well as advanced or metastatic triple-negative breast cancer in collaboration with Pfizer. It has a research and development collaboration agreement with the National Cancer Institute. The company was formerly known as Zenith Epigenetics Corp. and changed its name to Zenith Capital Corp. in August 2016. Zenith Capital Corp. was incorporated in 2013 and is headquartered in Calgary, Canada. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.03 | 150 | 0.02 | 0.05 | 0.0016 | 8049 | 0.03052278 | CS |
| 4 | -0.05 | -50 | 0.1 | 0.15 | 0.0016 | 11019 | 0.05650432 | CS |
| 12 | -0.08 | -61.5384615385 | 0.13 | 0.19 | 0.0004 | 8191 | 0.07914028 | CS |
| 26 | -0.02 | -28.5714285714 | 0.07 | 0.19 | 0.0003 | 12608 | 0.10348115 | CS |
| 52 | 0.01 | 25 | 0.04 | 0.19 | 0.0001 | 10679 | 0.09053368 | CS |
| 156 | -0.05 | -50 | 0.1 | 0.25 | 1.0E-6 | 13748 | 0.10503026 | CS |
| 260 | -0.2025 | -80.198019802 | 0.2525 | 0.45 | 1.0E-6 | 13424 | 0.13730546 | CS |
Transactions différées
Pour obtenir des transactions en temps réel, améliorez votre compte
Passer à la version en temps réel| Aucune Discussion Trouvée |
| Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
S'inscrire avec l'e-mail
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.
